Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells
By Bérengère Marty, Virginie Maire, Eléonore Gravier, Guillem Rigaill, Anne Vincent-Salomon, Marion Kappler, Ingrid Lebigot, Fathia Djelti, Audrey Tourdès, Pierre Gestraud, Philippe Hupé, Emmanuel Barillot, Francisco Cruzalegui, Gordon C Tucker, Marc-Henri Stern, Jean-Paul Thiery, John A Hickman and Thierry Dubois
(2007). Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol
(2006). Cryns VL: Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med
(2007). DF: American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
(2008). Essential roles of PI(3)Kp110beta in cell growth, metabolism and tumorigenesis. Nature
(2003). ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA
(2001). Eystein Lonning P, BorresenDale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA
(2004). F: A Model-Based Background Adjustment for Oligonucleotide Expression Arrays.
(2005). Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
(2006). Ganesan S: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell
(2005). GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov
(2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell
(2007). Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF1R-dependent mechanism. Oncogene
(2003). Huang AT: Gene expression predictors of breast cancer outcomes. Lancet
(2007). Integrated profiling of basal and luminal breast cancers. Cancer Res
(2008). IO: Basal-like breast cancer: a critical review.
(2007). JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature
(2001). JS: Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol
(2006). LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet
(2006). Maehara Y: Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer
(2007). Maehara Y: Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat
(2008). Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res
(2007). MD: Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J
(2004). Meric-Bernstam F: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res
(2004). Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res
(2008). Meta-analysis of gene-expression profiles in breast cancer: toward a unified understanding of breast cancer sub-typing and prognosis signatures. Breast Cancer Res
(2000). Molecular portraits of human breast tumours. Nature
(2008). Monni O: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
(2006). Moreau-Gachelin F: Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene. Oncogene
(2006). N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res
(2004). Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res
(2006). Perou CM: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol
(2006). Petricoin EF 3rd: Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer.
(2005). Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res
(2005). R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res
(2007). RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol
(2004). Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol
(2002). SH: Gene expression profiling predicts clinical outcome of breast cancer.
(2008). SH: Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias.
(2007). Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol
(2008). Stokoe D: A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isotype-selective inhibition.
(2008). Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol
The Curie Institute microarray dataset repository [ h t t p : / /
(2006). The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics
The R Project for Statistical Computing [http://www.rproject.org]
(2007). Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci
(2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
(2008). Tutt AN: Triple negative tumours: a critical review. Histopathology
(2004). Utz PJ: Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med
(2007). Vijver MJ van de: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res
(2005). Vincent-Salomon A: KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol
(2007). Watabe K: Roles of AKT signal in breast cancer. Front Biosci
(2007). WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene